Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. It also owns a 100% interest in the Frances Creek barium sulfate (barite) project, which is a rare grade mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.


TSXV:VM - Post by User

Post by postie1on Mar 23, 2021 9:21am
202 Views
Post# 32857024

News

News

They are still moving forward. Very quiet company just implementing a businee plan and not all hype.


"Calgary, Alberta – 
TheNewswire - March 22 nd , 2021 – Voyageur Pharmaceuticals Ltd. TSX.V VM USA (OTC VYYRF) (the "Company" or "Voyageur") announces that it has signed a cost plus manufacturing agreement with Alberta Veterinarian Laboratories Ltd. ("AVL"). This agreement allows Voyageur to begin the process of formulating and testing our new products with AVL and prepare for production and sales. AVL is committing mixing and fill lines for Voyageur's production. Voyageur and AVL are working jointly to create high quality health products for the clinical radiology market. AVL will be responsible for all Active Pharmaceutical Ingredients ("API") formulation, bottling and packaging. Voyageur will focus on country by country regulatory approvals, marketing, sales, logistics, distribution and supply-chain management to enter the North American market and new markets worldwide.

Voyageur will be finalizing the product lines and implementing final testing of products prior to full production start up. The pre-production phase is estimated to be completed in Q4 2021 and entails packaging design, fill line design & testing, laboratory batch testing, client batch testing, forward sales and marketing.

AVL recently completed construction in January 2021, of its modern and state of the art Good Manufacturing Practice ("GMP") pharmaceutical manufacturing facility. AVL received its Drug Establishment Licence (DEL) and have passed the inspection and are in full compliance for manufacturing, testing, distribution, importing API and labelling of powders, solutions, suspensions, pastes, ointments. Voyageur is excited to work with AVL and to continue to move Voyageur towards cash flow and full integration of its barium radiographic product lines and barium quarry."

<< Previous
Bullboard Posts
Next >>